Home › Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia clinical trials recruiting in the U.S.
122 studies for Chronic Lymphocytic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA31 studies
- Columbus, OH29 studies
- Durham, NC28 studies
- Washington, DC22 studies
- Seattle, WA22 studies
- Rochester, MN20 studies
- New York City, NY20 studies
- Houston, TX18 studies
- Baldwin Park, CA18 studies
- Cincinnati, OH15 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
- Nashville, TN13 studies
- Jacksonville, FL11 studies
- Atlanta, GA11 studies
- Philadelphia, PA11 studies
- Dallas, TX10 studies
- Portland, OR10 studies
- San Diego, CA10 studies
- Kansas City, MO10 studies
- Salt Lake City, UT10 studies
- Pittsburgh, PA10 studies
- Winston-Salem, NC9 studies
- Denver, CO9 studies
- Miami, FL9 studies
- Charlotte, NC9 studies
- Queens, NY8 studies
- Tampa, FL8 studies
- Minneapolis, MN8 studies
- Cleveland, OH8 studies
- Omaha, NE8 studies
- Los Angeles, CA8 studies
- Detroit, MI8 studies
- Des Moines, IA8 studies
- Fort Wayne, IN7 studies
- Newark, NJ7 studies
- St. Louis, MO7 studies
- Irvine, CA7 studies
- Cedar Rapids, IA7 studies
- Billings, MT7 studies
By state
- Alabama7 studies
- Arizona15 studies
- Arkansas4 studies
- California34 studies
- Colorado17 studies
- Connecticut5 studies
- Delaware4 studies
- District of Columbia4 studies
- Florida34 studies
- Georgia16 studies
- Idaho4 studies
- Illinois17 studies
- Indiana12 studies
- Iowa10 studies
- Kansas7 studies
- Kentucky7 studies
- Louisiana7 studies
- Maine6 studies
- Maryland23 studies
- Massachusetts33 studies
- Michigan13 studies
- Minnesota30 studies
- Mississippi5 studies
- Missouri12 studies
- Montana7 studies
- Nebraska8 studies
- Nevada6 studies
- New Hampshire3 studies
- New Jersey15 studies
- New Mexico3 studies
- New York27 studies
- North Carolina35 studies
- Ohio44 studies
- Oklahoma4 studies
- Oregon16 studies
- Pennsylvania22 studies
- Rhode Island6 studies
- South Carolina5 studies
- South Dakota3 studies
- Tennessee16 studies
- Texas39 studies
- Utah10 studies
- Virginia12 studies
- Washington27 studies
- West Virginia3 studies
- Wisconsin19 studies
Recently updated studies
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Nov 12, 2026 · NCT00923507A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05645107Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT01087333Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04269902Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04844528A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06846671Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06967610ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07342478Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
RecruitingEarly phase 1
Ages 18 to 100 · All sexes · Updated Nov 12, 2026 · NCT07428707Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07734038Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07582159A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05947851HPC Offered for PRESERVE Expansion
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05091424A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06588478A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07218341Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Nov 3, 2026 · NCT07321652Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07520006A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07221500Family Study of Lymphoproliferative Disorders
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Nov 2, 2026 · NCT00626496Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06839053A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 30, 2026 · NCT06520098A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07508995Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Oct 29, 2026 · NCT05724121From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.